Mounjaro: tirzepatide for type 2 diabetes
Mounjaro is the brand name for injectable tirzepatide manufactured by Eli Lilly, approved for type 2 diabetes treatment. Like Zepbound, it acts on both GIP and GLP-1 receptors.
Editorial and content standards team
NoGuiltMeds does not prescribe or promise approval. This content exists to orient the patient before evaluation.
Brand notice: NoGuiltMeds is not affiliated with the manufacturers of these medications. Trademarks mentioned belong to their respective owners. Compounded products are not equivalent to FDA-approved brand-name products.
What this page helps resolve
Use it as a reference, not a promise
NoGuiltMeds is not affiliated with the manufacturers of these medications. Trademarks mentioned belong to their respective owners. Compounded products are not equivalent to FDA-approved brand-name products.
Interactive module
Use it as a reference, not a promise
NoGuiltMeds is not affiliated with the manufacturers of these medications. Trademarks mentioned belong to their respective owners. Compounded products are not equivalent to FDA-approved brand-name products.
Frequently asked questions
Mounjaro contains tirzepatide, which has shown significant weight reduction in clinical studies, but it is approved for type 2 diabetes.
You might also like
Evaluation
Carry this page into the quiz.
The site wins when every education page pushes toward a useful action. Here, that action is still the evaluation.
Start evaluation